GSK India Unit Expects Benefits From Swap For Novartis Vaccine Portfolio
This article was originally published in PharmAsia News
Executive Summary
The trade of businesses GlaxoSmithKline and Novartis made in April, GSK getting a vaccine portfolio, Novartis an oncology business, is expected to rebound in the favor of the U.K.-based drug maker's India unit.